Clinical trial · Observational
Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer
Intratumoral Heterogeneity on [18F]PSMA-1007 and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Primary Prostate Cancer
NCT06919159CI-TRIAL-00088459completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to analyze heterogeneity of prostate cancer（PCa）based on the head-to-head imaging of prostate-specific membrane antigen (PSMA) and fluorodeoxyglucose (FDG) positron emission tomography computed tomography (PET/CT)
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Positron Emission Tomography (PET) | — | UNRESOLVED | — |
| Prostate Cancer (Diagnosis) | Malignant Prostate Neoplasm | CURATED_EXACT | 0.85 |
| Prostate-specific Membrane Antigen | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDG-PET | Diagnostic Test | — | UNRESOLVED |
| PSMA PET/CT scan | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- double positive group
- description
- patients with one type of PSMA+/FDG+ homogeneous segment
- interventionNames
- Diagnostic Test: PSMA PET/CT scan
- Diagnostic Test: FDG-PET
- label
- double negative group
- description
- patients with one type of PSMA-/FDG- homogeneous segment
- interventionNames
- Diagnostic Test: PSMA PET/CT scan
- Diagnostic Test: FDG-PET
- label
- PSMA predominant group
- description
- patients with one type of PSMA+/FDG- heterogeneous segment
- interventionNames
- Diagnostic Test: PSMA PET/CT scan
- Diagnostic Test: FDG-PET
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Untreated patients with PCa confirmed by prostate systemic pathological biopsy * Patients underwent \[18F\]PSMA-1007 and \[18F\]FDG PET/CT and the imaging interval was less than one month. Exclusion Criteria: * Patients received treatment at intervals of two imaging * Imaging was less than 1 week after pathology biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.